

We create a future  
for medical cannabis  
throughout Europe





NIKLAS KOUPARANIS  
CEO & FOUNDER

## Our Mission

Farmako GmbH is a research-based pharmaceutical company. Traditional research on pharmaceutical products has produced countless revolutions in the past century that have improved the lives of billions of people. Since the 1920s, however, research and development of pharmaceutical products based on the cannabis plant has been massively restricted or banned. We have set ourselves on helping to catch up on this research backlog of almost 100 years for cannabis based pharmaceuticals.

The Farmako is ready to drive this transformation worldwide.

## The European Market

Europe will be the largest cannabis market in the world, by the year 2028. Known for its considered and conservative approach to change, Europe is suddenly becoming a hotbed of activity for the global cannabis industry. Home to a population of over 742 million, more than double the US and Canada combined, Europe is a global economic powerhouse with an annual GDP of over €15t in 2017 and a total annual healthcare spend of €2.3t

**€110<sup>b</sup>**

Value of the combined european cannabis market (medical + recreational) in 2028

**€200<sup>m</sup>**

Value of the combined european cannabis market (medical + recreational) in 2018



€7.8<sup>b</sup>

Forecast Medical  
Cannabis Market  
Value 2028

€8.5<sup>b</sup>

Forecast Medical  
Cannabis Market  
Value 2028

## German Market


The German market for medical cannabis is estimated at 19.1 million euros in 2018. By 2019, the market in Germany is expected to grow to around 200 million euros. For 2028, experts expect a market volume for medical cannabis of 7.8 billion euros in Germany, an increase by a factor of 400.

€8.8<sup>b</sup>

Forecast Medical  
Cannabis Market  
Value 2028

€9.6<sup>b</sup>

Forecast Medical  
Cannabis Market  
Value 2028



## UK Market

It is estimated that there are as many as 3.6 million active cannabis users in the UK, contributing to an estimated black market value of up to €6b per year. In addition, according to research medical cannabis can treat up to 2.9 million patients in the UK.




SEBASTIAN DIEMER

CO-FOUNDER AND MANAGING  
DIRECTOR

## The Goal

Farmako plans to become a vertically integrated leader in every European country with a legal basis in this market. Farmako already has branches in Germany and the United Kingdom. The company relies on medical cannabis and focuses on research to develop new pharmaceutical products such as capsules, oils or inhalers.



## R&D makes the difference

We are a research based pharmaceutical company. On January 9th, we will publish the first of many patents to come. And this is just the beginning. Our research and development will continue to disclose upcoming patents in January and February in the upcoming year.





### NIKLAS KOUPARANIS

Niklas Kouparanis was the second employee and authorized officer of one of the currently leading German companies for medical cannabis. He shaped the industry as an established expert in the field, consultant to European governments, and supervisor to one of the first German-Canadian market entrances.



### PATRICK SCHMITT

Patrick Schmitt is molecularbiologist, state-approved pharmaceutical consultant and certified expert for medicine, drugs and nutritional supplements. He has several years of experience in product development and advising pharmaceutical companies and authorities on regulatory issues. He is also one of the most sought after experts for development, patent registration, licensing and evaluation of functional foods and drugs. His work has already found expression in over 500 products on the market and a large number of registred patents. At Farmako, he leads research and development. He is founder and shareholder



### TORSTEN RÖSSING

Torsten is the managing partner of Ewald & Rössing, a crisis management consultancy. He is the regional chairman of the German Public Relations Association in Hesse, Rhineland-Palatinate and Saarland. At Farmako, he manages regulation and privacy. He is founder and shareholder.



### SEBASTIAN DIEMER

Sebastian is often described as one of Germany's most successful founders. He has already successfully set up five companies, creating more than 1,000 jobs and raising over € 300 million in venture capital. His companies always pursued a global focus. He is founder and shareholder.



### MARCUS EWALD

Marcus is the managing partner of Ewald & Rössing, a crisis management consultancy. He is the federal chairman of the Young Economic Council of Germany, founded the Federal Blockchain Association and the Federal Association of AI. At Farmako, he directs public relations and public affairs. He is founder and shareholder.



### MARIO REICHENBACH

Mario was one of the first employees of one of the first and largest companies in the German cannabis market. He has successfully established an exenplary business development there and is one of the experts in the industry.

## Managing Team



# Farmako Local Offices


With offices in 8 European countries we already have an advantage over any other player

## Farmako GmbH

Our main office is in Frankfurt, Germany

## Global Presence

We're already present in multiple countries in Europe with plans to have offices in every country of European Union by 2020.



With Canada and California, two huge markets have already revolutionized their healthcare. The German market alone is almost as big as these two together. Together, European markets will become the global powerhouse of medical cannabis.

**And Farmako will lead that revolution in Europe.**

---

The Truth

